Announcements Trials
Browse Landscape

Phase

Phase 3 4Phase 1/2 1

Status

Completed 5

Sponsor Class

INDUSTRY 5

Study Type

Interventional 5

Sponsor

Cancer Type

Classical hematology 1

Conditions

Carcinoma, Non-Small-Cell Lung 57Breast Neoplasms 34Neoplasms 31Parkinson Disease 4, Autosomal Dominant Lewy Body 25Multiple Myeloma 20Recurrence 19Leukemia, Myeloid, Acute 19Neoplasm Metastasis 17Colorectal Neoplasms 16Lymphoma, Non-Hodgkin 15Melanoma 13Leukemia, Lymphocytic, Chronic, B-Cell 13Leukemia 13Ovarian Neoplasms 12Lymphoma, Follicular 12Carcinoma, Renal Cell 12Precursor Cell Lymphoblastic Leukemia-Lymphoma 11Myelodysplastic Syndromes 11Urinary Bladder Neoplasms 10Lung Neoplasms 10Lymphoma, Mantle-Cell 9Lymphoma, Large B-Cell, Diffuse 9Leukemia, Myelogenous, Chronic, BCR-ABL Positive 9Hematologic Neoplasms 9Carcinoma, Hepatocellular 9Adenocarcinoma 9Stomach Neoplasms 8Small Cell Lung Carcinoma 8Prostatic Neoplasms 8Lymphoma, B-Cell, Marginal Zone 8

Interventions

fostamatinib 3romiplostim 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

5 trials
RecentStart dateEnrollment
INDUSTRY × Has announcements × Purpura, Thrombocytopenic, Idiopathic × Clear all
NCT02077192 2023-12-11

Open Label Study of R788 in the Treatment of Persistent/Chronic Immune Thrombocytopenic Purpura (ITP)

Rigel Pharmaceuticals

Phase 3 Completed
123 enrolled 11 charts 1 FDA

Purpura, Thrombocytopenic, Idiopathic

NCT02076399 2019-02-12

FIT

Rigel Pharmaceuticals

Phase 3 Completed
76 enrolled 17 charts 1 FDA

Purpura, Thrombocytopenic, Idiopathic

NCT02076412 2019-01-25

FIT

Rigel Pharmaceuticals

Phase 3 Completed
74 enrolled 17 charts 1 FDA

Purpura, Thrombocytopenic, Idiopathic

NCT01444417 2017-02-09

Safety and Efficacy Study of Romiplostim to Treat Immune Thrombocytopenia (ITP) in Pediatric Patients

Amgen

Phase 3 Completed
62 enrolled 16 charts 1 FDA
Classical hematology

Purpura, Thrombocytopenic, Thrombocytopenia, Purpura, Thrombocytopenic, Idiopathic

NCT00515203 2014-07-25

Safety and Efficacy Study of Romiplostim (AMG 531) to Treat ITP in Pediatric Subjects

Amgen

Phase 1/2 Completed
22 enrolled 13 charts 1 FDA

Purpura, Thrombocytopenic, Purpura, Thrombocytopenic, Idiopathic

Data powered by HemOnc (CC BY 4.0) Colophon âš¡